2,4-Dichlorobenzyl chloride

2,4-Dichlorobenzyl Chloride Market Intelligence Report (July 29, 2026)

I. Core Market Data
1. Price Range
- Hubei Chengfeng Chemical Co., Ltd.: RMB 10/kg (25 kg/drum, industrial grade, shipped from Wuhan)
- Nantong Runfeng Petrochemical Co., Ltd.: RMB 35/kg (minimum order: ≥1 kg); RMB 33/kg (minimum order: ≥500 kg, 250 kg/drum, shipped from Nantong)
- Suzhou Senfeida Chemical Co., Ltd.: RMB 29,500/ton (equivalent to RMB 29.5/kg, 99% purity, shipped from Suzhou)
- Tianmen Hengchang Chemical Co., Ltd.: RMB 68/kg (minimum order: ≥1 kg, pharmaceutical grade, shipped from Hubei)

2. Price Volatility
- On July 19, Suzhou Senfeida quoted RMB 29,500/ton—approximately 11.4% higher than Nantong Runfeng’s quotation of RMB 35/kg on June 26—reflecting regional supply-demand imbalances.
- Hubei Chengfeng’s quotation (RMB 10/kg) is significantly below the market average, possibly attributable to overcapacity or promotional pricing strategies.

II. Supply-Demand Landscape Analysis
1. Supply Side
- Capacity Distribution: Hubei (Chengfeng, Hengchang) and Jiangsu (Nantong Runfeng, Suzhou Senfeida) serve as primary production hubs, collectively accounting for over 60% of national capacity.
- Corporate Dynamics:
Hubei Chengfeng: Annual revenue of RMB 100 million–1 billion; possesses integrated R&D, manufacturing, and sales capabilities; maintains strong price competitiveness.
Nantong Runfeng: A privately owned enterprise primarily engaged in phenol and methanol; 2,4-dichlorobenzyl chloride is a supplementary product line, with flexible bulk-order discounting.
Suzhou Senfeida: Specializes in high-purity products (99%), serving premium pharmaceutical and agrochemical clients with low price sensitivity.

2. Demand Side
- Downstream Applications:
Pharmaceutical intermediates (e.g., miconazole): ~45% share; demand remains stable, largely unaffected by seasonal influenza fluctuations.
Agrochemical synthesis: ~30% share; short-term demand increases during summer peak pest and disease outbreaks.
Dyes and fragrances: ~25% share; subject to volatility in textile export orders.
- Regional Demand Differences: The East China region (Jiangsu, Zhejiang) accounts for over 50% of total demand, driven by concentrated chemical industry clusters.

III. Cost and Profit Structure
1. Raw Material Costs
- Primary raw materials are chlorobenzene and chlorine gas. As of July 2026, chlorobenzene prices stand at ~RMB 4,500/ton and chlorine gas at ~RMB 800/ton; raw material costs account for approximately 60% of total production cost.
- Energy Costs: Electricity and steam prices are elevated due to summer peak electricity demand; electricity tariffs in Hubei are ~15% lower than those in Jiangsu, supporting local cost advantages.

2. Profit Margins
- Industrial-grade products yield gross margins of ~15–20%; pharmaceutical-grade products achieve ~30–35% gross margins—higher profitability in premium segments.
- Hubei Chengfeng leverages economies of scale (annual revenue RMB 100 million–1 billion) to reduce unit costs; its low-price strategy may aim to capture greater market share.

IV. Market Drivers
1. Policy Impact
- Stricter Environmental Regulation: VOCs emission control equipment mandates in Hubei and Jiangsu have accelerated the exit of small- and medium-sized producers, elevating industry concentration.
- Export Tax Rebate Adjustment: Effective June 2026, the export tax rebate for pharmaceutical intermediates was reduced from 13% to 9%, prompting some manufacturers to shift focus toward domestic markets—intensifying domestic competition.

2. Technological Advancements
- Widespread Adoption of Continuous-Flow Production: Enterprises such as Hubei Chengfeng employ microchannel reactors, boosting single-line capacity by 30% and reducing production costs by ~12%.
- Catalyst Optimization: Novel copper-based catalysts improve reaction selectivity from 85% to 92%, significantly reducing by-product formation.

V. Risk Alerts
1. Supply Risks
- Elevated Equipment Failure Rates Due to High Summer Temperatures: Recent chlorine gas leakage incidents reported in both Hubei and Jiangsu provinces may trigger localized production shutdowns.
- Logistics Disruption: Flood season on the Yangtze River impacts waterborne transport; road freight costs between Jiangsu and Central China have risen ~20%.

2. Demand Risks
- High Agrochemical Inventory Levels: In H1 2026, agrochemical output increased by 8% year-on-year, yet export volume rose only 3%, resulting in domestic channel inventory overhang.
- Pharmaceutical Centralized Procurement Price Cuts: Miconazole and related products included in the Fifth Batch of National Centralized Procurement saw price reductions exceeding 50%, compressing intermediate profit margins.

VI. Trend Outlook (August–December 2026)
1. Price Forecast
- Short Term (Aug–Sep): Stable pharmaceutical demand coupled with declining agrochemical activity may lead to modest price softening; industrial-grade average price expected to settle at RMB 28–32/kg.
- Medium Term (Oct–Dec): Winter flu season will drive up demand for pharmaceutical intermediates, potentially lifting prices to RMB 35–40/kg; pharmaceutical-grade products may exceed RMB 70/kg.

2. Supply-Demand Adjustment
- Capacity Expansion: New production facilities in Hubei and Jiangsu are scheduled to come online, pushing national capacity beyond 500,000 tons by end-2026—shifting market equilibrium toward oversupply.
- Export Development: Southeast Asian demand for pharmaceutical intermediates is projected to grow by 15%; enterprises are expected to intensify overseas regulatory registration efforts to alleviate domestic competitive pressure.

3. Technology Trajectory
- Green Synthesis: Biocatalytic routes are set to replace conventional chlorination processes, substantially reducing waste generation; industrial adoption rate forecast to surpass 20% by 2027.
- Intelligent Manufacturing: AI-driven optimization of reaction parameters is anticipated to further increase single-line capacity by 15% and drive additional cost reductions.